J E Slansky
Overview
Explore the profile of J E Slansky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1069
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Capasso A, LANG J, Pitts T, Jordan K, Lieu C, Davis S, et al.
J Immunother Cancer
. 2019 Feb;
7(1):37.
PMID: 30736857
Background: The success of agents that reverse T-cell inhibitory signals, such as anti-PD-1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only a minority of patients respond to single-agent therapies,...
2.
Mitchell L, Dow S, Slansky J, Biller B
Vet Immunol Immunopathol
. 2012 Feb;
145(3-4):597-603.
PMID: 22293625
Characterization of the tumor microenvironment, particularly the immune cells that infiltrate tumors, provides important predictive and prognostic information in humans with lymphoma and other types of cancer. Tumor associated T...
3.
Schneck J, Slansky J, OHerrin S, Greten T
Curr Protoc Immunol
. 2008 Apr;
Chapter 17:Unit 17.2.
PMID: 18432743
The lack of high affinity reagents has made distinguishing T cells on the basis of antigen specificity difficult to accomplish. This unit provides protocols that utilize innovations in molecular design...
4.
OHerrin S, Slansky J, Tang Q, Markiewicz M, Gajewski T, Pardoll D, et al.
J Immunol
. 2001 Aug;
167(5):2555-60.
PMID: 11509595
Ag-specific immune tolerance in clinical organ transplantation is currently an unrealized but critical goal of transplant biology. The specificity and avidity of multimerized MHC-peptide complexes suggests their potential ability to...
5.
TSENG S, Otsuji M, Gorski K, Huang X, Slansky J, Pai S, et al.
J Exp Med
. 2001 Apr;
193(7):839-46.
PMID: 11283156
Dendritic cells (DCs), unique antigen-presenting cells (APCs) with potent T cell stimulatory capacity, direct the activation and differentiation of T cells by providing costimulatory signals. As such, they are critical...
6.
Slansky J, Rattis F, Boyd L, Fahmy T, Jaffee E, Schneck J, et al.
Immunity
. 2000 Nov;
13(4):529-38.
PMID: 11070171
T cell responsiveness to an epitope is affected both by its affinity for the presenting MHC molecule and the affinity of the MHC-peptide complex for TCR. One limitation of cancer...
7.
Greten T, Slansky J, Kubota R, Soldan S, Jaffee E, Leist T, et al.
Proc Natl Acad Sci U S A
. 1998 Jun;
95(13):7568-73.
PMID: 9636190
Human T lymphotropic virus type 1 (HTLV-1) -associated myelopathy/tropic spastic paraparesis is a demyelinating inflammatory neurologic disease associated with HTLV-1 infection. HTLV-1 Tax11-19-specific cytotoxic T cells have been isolated from...
8.
Fry C, Slansky J, Farnham P
Mol Cell Biol
. 1997 Apr;
17(4):1966-76.
PMID: 9121444
Activity of the dihydrofolate reductase (dhfr) promoter increases at the G1-S-phase boundary of the cell cycle. Mutations that abolish protein binding to an E2F element in the dhfr promoter also...
9.
Slansky J, Farnham P
Bioessays
. 1996 Jan;
18(1):55-62.
PMID: 8593164
As cells approach S phase, many changes occur to create an environment conducive for DNA synthesis and commitment to cell division. The transcription rate of many genes encoding enzymes involved...
10.
Slansky J, Farnham P
Curr Top Microbiol Immunol
. 1996 Jan;
208:1-30.
PMID: 8575210
E2F is a heterodimer composed of two partners, such as E2F1 and DP1. Although E2F1 can bind DNA as a homodimer and increase promoter activity, optimal DNA-binding and transcriptional activity...